Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer

Purpose: The prognostic value of circulating tumor cells (CTC) detected in breast cancer patients is currently under debate. Different time points of blood collections and various CTC assays have been used in the past decades. Here, we conducted the first comprehensive meta-analysis of published literature on the prognostic relevance of CTC, including patients with early and advanced disease. Experimental Design: A comprehensive search for articles published between January 1990 and January 2012 was conducted; reviews of each study were conducted and data were extracted. The main outcomes analyzed were overall survival (OS) and disease-free survival (DFS) in early-stage breast cancer patients, as well as progression-free survival (PFS) and OS in metastatic breast cancer patients. Pooled hazard ratio (HR) and 95% confidence intervals (CIs) were calculated using the random and the fixed-effects models. Subgroup and sensitivity analyses were also conducted. Results: Forty-nine eligible studies enrolling 6,825 patients were identified. The presence of CTC was significantly associated with shorter survival in the total population. The prognostic value of CTC was significant in both early (DFS: HR, 2.86; 95% CI, 2.19–3.75; OS: HR, 2.78; 95% CI, 2.22–3.48) and metastatic breast cancer (PFS: HR, 1.78; 95% CI, 1.52–2.09; OS: HR, 2.33; 95% CI, 2.09–2.60). Further subgroup analyses showed that our results were stable irrespective of the CTC detection method and time point of blood withdrawal. Conclusion: Our present meta-analysis indicates that the detection of CTC is a stable prognosticator in patients with early-stage and metastatic breast cancer. Further studies are required to explore the clinical utility of CTC in breast cancer. Clin Cancer Res; 18(20); 5701–10. ©2012 AACR.

• Publication year

  2012

• Venue

  Clinical Cancer Research

• Publication date

  2012-08-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-1587PMID 22908097
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.

  2012cited by this paper
• High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.

  2012cited by this paper
• Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer

  2012cited by this paper
• Circulating tumour cells in peripheral blood: potential impact on breast cancer outcome

  2011cited by this paper
• The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature

  2011cited by this paper
• Detection of circulating tumor cells by RT-PCR significantly associated with poor prognosis in breast cancer

  2011cited by this paper
• Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

  2011cited by this paper
• Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

  2011cited by this paper
• A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer

  2011cited by this paper
• Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization.

  2011influential reference
• Circulating Tumor Cells as Predictors of Prognosis in Metastatic Breast Cancer: Clinical Application outside a Clinical Trial

  2011cited by this paper
• Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

  2011cited by this paper
• Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer

  2010cited by this paper
• Detection of Cytokeratin 19, Human Mammaglobin, and Carcinoembryonic Antigen-Positive Circulating Tumor Cells by Three-Marker Reverse Transcription-Pcr Assay and Its Relation to Clinical Outcome in Early Breast Cancer

  2010cited by this paper
• Detection of circulating tumor cells in breast cancer patients utilizing multiparameter flow cytometry and assessment of the prognosis of patients in different CTCs levels

  2010cited by this paper
• Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer.

  2010cited by this paper
• Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer

  2010cited by this paper
• Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

  2010cited by this paper
• Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence

  2009cited by this paper
• Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.

  2009cited by this paper
• Characterization of Metastatic Breast Cancer Patients with Non-Detectable Circulating Tumor Cells.

  2009cited by this paper
• Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance

  2009cited by this paper
• Detection of circulating tumor Cells in the context of treatment: Prognostic value in breast cancer patients

  2009cited by this paper
• Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.

  2009cited by this paper
• Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer

  2009cited by this paper
• Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.

  2009cited by this paper
• Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.

  2009cited by this paper
• Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies

  2009cited by this paper
• Circulating tumor cells in metastatic breast cancer

  2008cited by this paper
• The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method

  2008cited by this paper
• Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan

  2008cited by this paper
• Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer

  2008cited by this paper
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

  2007cited by this paper
• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.

  2007cited by this paper
• Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells.

  2007cited by this paper
• Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.

  2007cited by this paper
• Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.

  2007cited by this paper
• Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer.

  2007cited by this paper
• Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.

  2007cited by this paper
• Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer

  2006cited by this paper
• Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.

  2006influential reference
• Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients

  2006cited by this paper
• Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer

  2006influential reference
• HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients

  2006cited by this paper
• Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer

  2006cited by this paper
• Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

  2006influential reference
• Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR.

  2006cited by this paper
• Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

  2005cited by this paper
• Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques

  2005cited by this paper
• A pooled analysis of bone marrow micrometastasis in breast cancer.

  2005cited by this paper
• Reporting recommendations for tumor marker prognostic studies.

  2005cited by this paper
• Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients.

  2005cited by this paper
• Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients

  2004cited by this paper
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

  2004cited by this paper
• Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse

  2004cited by this paper
• Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen‐receptor status and predicts for poor prognosis

  2003cited by this paper
• Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients

  2003cited by this paper
• Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.

  2003cited by this paper
• Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.

  2002cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper

• Decoding Breast Cancer: Emerging Molecular Biomarkers and Novel Therapeutic Targets for Precision Medicine

  2025cites this paper
• Liquid biopsy in breast cancer management: From circulating biomarkers to clinical breakthroughs

  2025cites this paper
• Redefining cancer care: harnessing circulating tumor cells’ potential for improved diagnosis and prognosis

  2025cites this paper
• From Discovery to Diagnosis: A Perspective for Circulating Tumor Cells in Personalized Oncology.

  2025cites this paper
• Identification of astrocytomas through serum protein fingerprint using MALDI-TOF MS and machine learning

  2025cites this paper
• Identification and Isolation Pipeline for Single Cell Transcriptomic of Magnetically Enriched Tumor Cells

  2025cites this paper
• The Combined Assessment of CTC and ESR1 Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer

  2025cites this paper
• Robust Automated Separation of Circulating Tumor Cells and Cancer-Associated Fibroblasts for Enhanced Liquid Biopsy in Breast Cancer.

  2025cites this paper
• Intraoperative Cell Salvage in Oncologic Surgery: A Comprehensive Review

  2025cites this paper
• Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications.

  2025cites this paper
• Liquid biopsy for the management of gastrointestinal cancers.

  2025cites this paper
• Breast Cancer Circulating Tumor Cells: Current Clinical Applications and Future Prospects.

  2024cites this paper
• HER2(-Low) Expression on Circulating Tumor Cells and Corresponding Metastatic Tissue in Metastatic Breast Cancer

  2024cites this paper
• Diagnostic and prognostic value of circulating tumor cells in renal cell cancer: A systematic review and meta-analysis.

  2024cites this paper
• Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression

  2024cites this paper
• Circulating tumor cells clusters and their role in Breast cancer metastasis; a review of literature

  2024cites this paper
• Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges

  2024cites this paper
• Recent progress in Surface-Enhanced Raman Spectroscopy detection of biomarkers in liquid biopsy for breast cancer

  2024cites this paper
• Detection, significance and potential utility of circulating tumor cells in clinical practice in breast cancer (Review)

  2024cites this paper
• Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma

  2024cites this paper
• Clinical applications of circulating tumor cells in patients with solid tumors

  2024cites this paper
• A Comprehensive Review and Meta-Analysis of CTC Isolation Methods in Breast Cancer.

  2024cites this paper
• Relationship of Ki-67 index in biopsies of metastatic breast cancer tissue and circulating tumor cells (CTCs) at the time of biopsy collection

  2023cites this paper
• Disease Assessments in Patients with Glioblastoma

  2023cites this paper
• An Image-Based Identification of Aggressive Breast Cancer Circulating Tumor Cell Subtypes

  2023cites this paper
• Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study

  2023cites this paper
• Fractional mathematical model underlying mixed treatments using endocrine diet therapy and immunotherapy for breast cancer

  2023cites this paper
• Duplex Phenotype Detection and Targeting of Breast Cancer Cells Using Nanotube Nanoprobes and Raman Imaging.

  2023cites this paper
• Automated Capture and Analysis of Circulating Tumor Cells in Pediatric, Adolescent and Young Adult Patients with Central Nervous System Tumors

  2023cites this paper
• Molecular aspects of brain metastases in breast cancer.

  2023cites this paper
• Raman Spectroscopy Combined with Malaria Protein for Early Capture and Recognition of Broad-Spectrum Circulating Tumor Cells

  2023cites this paper
• Factors influencing the diagnostic and prognostic values of circulating tumor cells in breast cancer: a meta-analysis of 8,935 patients

  2023cites this paper
• Liquid biomarkers in glioma

  2023cites this paper
• Deciphering the Biology of Circulating Tumor Cells through Single-Cell RNA Sequencing: Implications for Precision Medicine in Cancer

  2023cites this paper
• Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer

  2022cites this paper
• Vitamin D and circulating tumor cells in primary breast cancer

  2022cites this paper
• Application of nanomaterials in proteomics-driven precision medicine

  2022cites this paper
• Heparanase 1 Upregulation Promotes Tumor Progression and Is a Predictor of Low Survival for Oral Cancer

  2022cites this paper
• Advances in Microfluidics for the Implementation of Liquid Biopsy in Clinical Routine.

  2022cites this paper
• The Value of Circulating Tumor Cells in the Prognosis and Treatment of Pancreatic Cancer

  2022cites this paper
• Detection and Characterization of Estrogen Receptor α Expression of Circulating Tumor Cells as a Prognostic Marker

  2022cites this paper
• Studies on the Effect of Graphene Oxide Deposited on Gold and Nickel Microsieves on Prostate Cancer Cells DU 145

  2022cites this paper
• Meta-analysis of the prognostic value of circulating tumor cells in gastrointestinal cancer

  2022cites this paper
• Liquid biopsy-detecting molecular targets in cancer management

  2022cites this paper
• Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis

  2022cites this paper
• Malignancy Assessment Using Gene Identification in Captured Cells Algorithm for the Prediction of Malignancy in Women With a Pelvic Mass

  2022cites this paper
• Detection of Circulating Tumor Cells Using the Attune NxT

  2022cites this paper
• Microfluidic-Based Technologies for CTC Isolation: A Review of 10 Years of Intense Efforts towards Liquid Biopsy

  2022cites this paper
• Clinical Relevancy of Circulating Tumor Cells in Breast Cancer: Epithelial or Mesenchymal Characteristics, Single Cells or Clusters?

  2022cites this paper
• Diagnostic Value of Nonacid Nucleic Blood Tumor Marker Panels in Early Diagnosing Breast Cancer: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• The Role of Circulating Tumor Cells in the Prognosis of Metastatic Triple-Negative Breast Cancers: A Systematic Review of the Literature

  2022cites this paper
• Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients

  2022cites this paper
• Current and Developing Liquid Biopsy Techniques for Breast Cancer

  2022cites this paper
• Local release and isolation of circulating tumor cells captured by the nano-morphologic substrate coated with gelatin under near-infrared light

  2021cites this paper
• Detection of Multiple Breast Cancer ESR1 Mutations on an ISFET Based Lab-on-Chip Platform

  2021cites this paper
• Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy

  2021cites this paper
• Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells

  2021cites this paper
• A microfluidic robot for rare cell sorting based on machine vision identification and multi-step sorting strategy.

  2021cites this paper
• Inter-Reader Agreement of Diffusion-Weighted Magnetic Resonance Imaging for Breast Cancer Detection: A Multi-Reader Retrospective Study

  2021cites this paper
• The Role of Circulating Tumor Cells in Chemoresistant Metastatic Breast Cancer

  2021cites this paper
• Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker

  2021cites this paper
• Clusters, Assemblies and Aggregates of Tumor Cells in the Blood of Breast Cancer Patients; Composition, Mode of Action, Detection and Impact on Metastasis and Survival

  2021cites this paper
• ViBiBa: Virtual BioBanking for the DETECT multicenter trial program - decentralized storage and processing

  2021cites this paper
• Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue

  2021cites this paper
• Application of Primary/Secondary Circulating Tumor Cells for the Prediction of Biochemical Recurrence in Nonmetastatic Prostate Cancer Patients following Radical Prostatectomy or Radiotherapy: A Meta-Analysis

  2021cites this paper
• Exosome-based liquid biopsies in cancer: opportunities and challenges

  2021cites this paper
• Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease

  2021cites this paper
• Breast Cancer Recurrence and Survival

  2021cites this paper
• Detection of circulating tumor cells as therapeutic markers in patients with penile squamous cell carcinoma: A preliminary study

  2021cites this paper
• Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications

  2020cites this paper
• Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression.

  2020cites this paper
• Circulating Tumor Cells as Biomarkers in Pancreatic Cancer

  2020cites this paper
• Evaluating Donor Effects in Isoindigo-Based Small Molecular Fluorophores.

  2020cites this paper
• Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy

  2020cites this paper
• Enrichment and detection of circulating tumor cells by immunomagnetic beads and flow cytometry

  2020influential citation
• Enrichment and detection of circulating tumor cells by immunomagnetic beads and flow cytometry

  2020cites this paper
• Comment for the "EpCAM-based Flow Cytometric Detection of Circulating Tumor Cells in Gallbladder Carcinoma Cases".

  2020cites this paper
• Preclinical and Clinical Evaluation of Magnetic-Activated Cell Separation Technology for CTC Isolation in Breast Cancer

  2020cites this paper
• Non-Invasive Biomarkers for Early Detection of Breast Cancer

  2020cites this paper
• Detection of Circulating Tumor Cells and Cell Free DNA in Cancer Management

  2020cites this paper
• In Vivo Detection of CTC and CTC Plakoglobin Status Helps Predict Prognosis in Patients with Metastatic Breast Cancer

  2020cites this paper
• and Characteristics of Circulating Tumor Cells in Breast Cancer

  2020cites this paper
• MAGE-A genes as predictors of the outcome of laryngeal squamous cell carcinoma.

  2020cites this paper
• Circulating tumour cells in head and neck cancers: Biological insights.

  2020cites this paper
• Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer

  2020cites this paper
• High-Efficiency Light-Induced Circulating Tumor Cells Screening Biochip Prepared by 40.68-MHz VHFPECVD

  2020cites this paper
• Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal

  2020cites this paper
• Methodology for the Isolation and Analysis of CTCs.

  2020cites this paper
• Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer.

  2020cites this paper
• Circulating tumor cells and breast cancer-specific mutations in primary breast cancer.

  2020influential citation
• Relevance of CTC Clusters in Breast Cancer Metastasis.

  2020cites this paper
• Circulating Tumor Cells in Breast Cancer Metastatic Disease

  2020cites this paper
• Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer

  2020cites this paper
• Cancer stem cells and combination therapies to eradicate them.

  2020cites this paper
• Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma

  2020cites this paper
• Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2

  2020cites this paper
• Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?

  2020cites this paper
• Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value

  2020cites this paper
• Challenges and achievements of liquid biopsy technologies employed in early breast cancer

  2020cites this paper
• Circulating tumor cells and drug history in primary breast cancer patients

  2020cites this paper